Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MC1R | Q01726 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482193 | 1.00 | MC5R (0.70) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL6008064 | 0.90 | MC5R (0.70) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL3242373 | 0.86 | MC5R (0.67) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL21296202 | 0.86 | MC5R (0.67) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL15131007 | 0.86 | MAPK1 (0.67) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL15130991 | 0.86 | MC5R (0.67) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL9080754 | 0.85 | MC5R (0.66) | MC5RMAPK1KMT2AMEN1MC1R | |
| Hydrochloric Acid SCHEMBL31146828 | 0.84 | MC5R (0.65) | MC5RMAPK1KMT2AMEN1MC1R | |
| SCHEMBL2343213 | 0.84 | HPGD (0.62) | MC5RMAPK1KMT2AMEN1HPGD | |
| SCHEMBL15131004 | 0.84 | CA12 (0.68) | MC5RMAPK1KMT2AMEN1MC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102834379-A | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD | 2012-12-19 | — | — | CN | claimed |
| US-20020107406-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | US | claimed |
| EP-0933354-A1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-04 | — | — | EP | claimed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2024-09-10 | — | — | US | disclosed |
| EP-3603647-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO LTD (KR) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | FUTURE MEDICINE CO., LTD. (KR) | 2021-12-16 | — | — | US | disclosed |
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | FUTURE MEDICINE CO., LTD. (KR) | 2021-11-30 | — | — | US | disclosed |
| EP-0585202-A1 | N,N'-alkenylene amine/mercaptotolyl-imidazole blends as high temperature antioxidants for elastomers | CIBA-GEIGY AG (CH) | 1994-03-02 | — | — | EP | disclosed |
| US-5283367-A | Antioxidants for lubricants and polymers | CIBA-GEIGY CORPORATION (US) | 1994-02-01 | — | — | US | disclosed |
| US-5240976-A | For automobile, wire and cable uses | CIBA-GEIGY CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-5196164-A | During addition polymerization, wall coating of anionic dye and cationic dye and organonitrogen compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0514333-A2 | Substituted 1,4-diamino-2-butene stabilizers and stabilized compositions | CIBA-GEIGY AG (CH) | 1992-11-19 | — | — | EP | disclosed |
| EP-0355575-A2 | Method of preventing polymer scale formation | Shin-Etsu Chemical Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | MC5R 553/4885MAPK1 3230/4885KMT2A 2276/4885 |
| US-11185556-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, PDE3A | MC5R 993/4885MAPK1 651/4885KMT2A 4100/4885 |
| US-12083140-B2 | Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative | ADORA1, ADORA2A, ADORA3 | MC5R 1034/4885MAPK1 721/4885KMT2A 4047/4885 |
| US-20210386771-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE | ADORA1, ADORA2A, ADORA3 | MC5R 1034/4885MAPK1 721/4885KMT2A 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.